All News

flu

Influenza Vaccination Recommendations

d CDC

The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season.

Read Article
RheumNow Podcast square

RheumNow Podcast –Rainbow Rheumatology (8.27.2022)

d Jack Cush, MD

Dr. Jack Cush delivers this weeks rheumatology "weather report" with the best and least of news and journal articles from the past week on RheumNow.com



“Climate is what we expect, weather is what we get.” – Mark Twain

Read Article
IL-6 IL6 cells cytokine

Olokizumab, another IL-6 Inhibitor for RA

d Jack Cush, MD

This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.

This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6 receptor.

Read Article
joint.injx_.jpg

Hyaluronic Acid Knee Injections Equivalent to Placebo

d Jack Cush, MD

In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.

Read Article
Review of VTE risk with JAK inhibitors - Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk factors, VTE 0.35/100PY - Baricitinib: IR of DVT/PE was 0.5/100PY - Filgotinib: 200mg VTEs 0.2/100PY Most VTE occured in LT extension of RCT https://t.co/xvf0kQUMel https://t.co/Bj6fmkktP7

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush delivers this weeks rheumatology "weather report" with the best and least of news and journal articles from the past week on RheumNow. Are you a fan of our podcast? Please rate, like and review us wherever you get your podcast. https://t.co/uj6QF3EqlU https://t.co/lFpoRfkEqU

Links:

Dr. John Cush RheumNow ( View Tweet)
Melatonin Use Growing, Inappropriate & Potentially Unsafe With nearly 1/3 of adults, adolescents and children having sleep difficulties, many resort to using melatonin. But is it effective, safe and warranted? https://t.co/8TA76yAbwr https://t.co/ADYklo0yMz

Links:

Dr. John Cush RheumNow ( View Tweet)
Olokizumab, another IL-6 Inhibitor for RA This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets interleukin-6 (IL-6) in patients with rheumatoid arthritis (RA). https://t.co/VMz8xzffiZ https://t.co/eaA4CUWvrv

Links:

Dr. John Cush RheumNow ( View Tweet)
Hyaluronic Acid Knee Injections Equivalent to Placebo In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo. https://t.co/1pSVr3VI4t https://t.co/DvFN7WQdTp

Links:

Dr. John Cush RheumNow ( View Tweet)
Bullous Systemic Lupus Erythematosus (BSLE) BSLE is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE). As goes SLE, bullous disease typically affects women, especially those of African descent. https://t.co/TBr7pGXjZ5 https://t.co/aq5dX3wQPX

Links:

Dr. John Cush RheumNow ( View Tweet)
Record Use of Marijuana and Hallucinogens in Young Adults The NY Times reports that a recent survey of drug use indicates that daily consumption of marijuana among young adults nearly doubled in the last decade. https://t.co/Dvj4nUNdtg https://t.co/BRkq8nb5sz

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase 2 RCTs are evaluating TLR 7 & TLR 8 blockade in SLE - BMS has afimetoran and Merck has enpatoran (both blocking TLR7/8) https://t.co/3TavS7NE99 https://t.co/lZyp1QLNqP

Links:

Dr. John Cush RheumNow ( View Tweet)
Myths & Misconceptions with Febrile Disorders Still’s disease and autoinflammatory disorders are rare conditions unified by recurrent fevers and inflammation of skin, joints, and other organs. https://t.co/vdZWR1cwDx https://t.co/OoGIBjpZGn

Links:

Dr. John Cush RheumNow ( View Tweet)
Top 60 brand-name drugs in US cost ~395%higher than other high-income countries. New legislation by Congress lets Medicare negotiate drug prices & cap out-of-pocket costs @$2,000/yr. Read more on proposed restrictions importing drugs from Canada https://t.co/z507qRNj4E https://t.co/kXnqIQkIp7

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 9611 pts w/ hip or knee arthroplasty for #OA tested aspirin (100 mg/d) vs enoxaparin (40 mg/d) (x35d w/THA; 14d after TKA). Enrollment prematurely halted as VTE rate was 3.45% w/ ASA and 1.8% w/ enoxaparin (superior to ASA: P= .007) https://t.co/jvuely8L56 https://t.co/O1TxCjaSPU

Links:

Dr. John Cush RheumNow ( View Tweet)
VTE (clots) w/ JAK inhibitors? Metanalysis of JAKi in 9711 Atopic dermatitits pts shows no significant assoc between JAK and incident VTE (HR 0.95; CI 0.62-1.45; or 0.23 VTE/100PYs). Actual #s: 3 VTE per 5722 pts (0.05%) https://t.co/VesXp5WSpY https://t.co/JsFSKzmbjN

Links:

Dr. John Cush RheumNow ( View Tweet)
Eval of 161 acute mono/oligoarthritis pts (gout, CPPD, controls) shows US of 2 joints (target jt, knee, MTP1, wrist) showed Dx accuracy (>90%), high specificity for gout (0.92-0.96) & CPPD (0.90-0.97); w/ sensitivity ranged from 0.73 to 0.85 for gout https://t.co/hW3pmz86kH https://t.co/IFVpINgybY

Links:

Dr. John Cush RheumNow ( View Tweet)
NICE has approved upadacitinib (Rinvoq) for availability in England & Wales for use in adults w/ active ankylosing spondylitis not controlled with conventional therapy, only after TNF inhibitors are tried or not suitable https://t.co/MV47NPb2EF https://t.co/9Le2Sj5aNI

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA Patient Handout on common causes of patient hair loss 1. Patterned: androgenetic alopecia 2. Diffuse: telogen effluvium 3. Focal: alopecia areata https://t.co/caL41RdxaV https://t.co/WsStH3drMk

Links:

Dr. John Cush RheumNow ( View Tweet)
Bidirectional Association Between Depression and Rheumatoid Arthritis A recent meta-analysis suggests a bidirectional association between RA and depression. Finding RA patients with depression yields an 80% increased mortality risk. https://t.co/1o2ObHd76V

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×